Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4582 Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,

#4475 Retreatment with [177Lu]Lu-DOTATATE in neuroendocrine tumours: Outcomes in progression-free survival and toxicity – Our experience

Introduction: Multiple systemic treatments exist for advanced or metastatic NETs, including somatostatin analogues, targeted agents, chemotherapy, and peptide receptor radionuclide therapy (PRRT). PRRT has shown maximum benefit for response rate, progression-free survival (PFS), and overall survival (OS) with favourable toxicity.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Mari Hualde A, Ardila Manjarés E, Guzman Cruz A, Orcajo Rincón J,

Keywords: Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTATATE, Retreatment (R-PRRT), Toxicity, Progression-free survival (PFS), Overall survival (OS),

#4111 Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Peptide receptor radionuclide therapy (PRRT) presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known.

Conference:

Presenting Author: Warfvinge C

Authors: Warfvinge C, Gustafsson J, Roth D, Tennvall J, Svensson J,

Keywords: PRRT, Neuroendocrine tumor, dose-response, dosimetry,

#4051 TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms

Introduction: The radiolabelled somatostatin receptors (SSTR) agonist development was a milestone in the management of neuroendocrine tumors (NEN), however the SSTR antagonist recognize more binding sites on NEN cells which should improve the diagnostic efficacy. The development of technetium-99m based radiopharmaceuticals should improve access to this clinically feasible diagnostic tool.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Virgolini I, Lezaic L, Decristoforo C, Kolenc P,

Keywords: NET, SSTR antagonist, SPECT/CT, SSTR, TECANT, [99mTc]Tc-TECANT1,

#3875 Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,